相关实验视频

Updated: Feb 26, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

治疗诱导的神经内分泌前列腺癌的基因和表观遗传机制

Viriya Keo¹, Xiaodong Lu¹, Jonathan C Zhao^2,3

¹Department of Urology, Emory University School of Medicine, Atlanta, United States.

Journal of the National Cancer Center

|February 25, 2026

概括

治疗诱导的神经内分泌前列腺癌 (t-NEPC) 发生于晚期前列腺癌 (PCa) 治疗. 表观遗传变化,而不仅仅是基因,驱动了这种致命的亚型.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学

背景情况:

治疗诱导的神经内分泌前列腺癌 (t-NEPC) 是割耐性前列腺癌 (CRPC) 的致命亚型.
由于在晚期前列腺癌 (PCa) 中使用雄激素受体通路抑制剂 (ARPi),其发病率上升.
与CRPC相比,t-NEPC表现出不同的表观遗传程序,尽管保留了基因组变化.

研究的目的:

审查t-NEPC的遗传驱动因素.
在PCa中全面检查神经内分泌转化 (NET) 期间的2D和3D染色质变化.
确定这些表观遗传程序的关键分子调节器.

主要方法:

在t-NEPC.中对遗传驱动因素的审查.
在PCa NET期间对二维和三维染色质变化 (DNA甲基化,基因组修饰,染色质可访问性,三维组织) 的全面审查.
对分子调节者的审查,包括转录因子和染色质修饰剂.

主要成果:

在CRPC和t-NEPC之间,基因组变化在很大程度上保持不变.
表观遗传程序显著不同,涉及显著的染色质改变.
关键的分子调节者,包括转录因子和染色质修饰剂,协调这些表观遗传变化.

结论:

表观遗传重编程是前列腺癌神经内分泌转换的关键机制.
克隆选择和转变的混合模型可能推动NEPC的进展.
了解这些表观遗传机制对于开发针对t-NEPC的新治疗策略至关重要.

关键词:

染色是一种染色素.克隆选择克隆选择表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.血统的可塑性血统的可塑性甲基化甲基化甲基化神经内分泌前列腺癌是神经内分泌前列腺癌.转录因子转录因子

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...